Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
Astellas Pharma said on September 20 that ASP0113, its investigational cytomegalovirus (CMV) vaccine being developed with US partner Vical, failed to meet the primary endpoint in a multinational PII study covering kidney transplant patients. The randomized, double-blind, placebo-controlled study looked…
To read the full story
Related Article
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
BUSINESS
- Otsuka’s Centanafadine Accepted for FDA Review with Priority Tag
January 28, 2026
- Sato Enters Smoking Cessation Market via Nicotinell Tie-Up with Dr. Reddy’s
January 27, 2026
- Top Court Rejects Samsung Challenge to Patent-Linkage Disclosures in Eylea Biosimilar Case
January 27, 2026
- Quviviq, Dayvigo Top 3 Promotion Channels in December: Intage
January 27, 2026
- Ajinomoto Builds Presence in ADC CDMO Business with Proprietary Technology
January 27, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…